Tokyo, Nov. 18 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059801) titled 'Investigation of ctDNA gene alterations associated with treatment resistance in RAS wild-type metastatic colorectal cancer' on Nov. 18.
Study Type:
Observational
Primary Sponsor:
Institute - National Cancer Center
Condition:
Condition - Colorectal cancer
Classification by malignancy - Malignancy
Genomic information - YES
Objective:
Narrative objectives1 - To characterize changes in genomic alterations before and after chemotherapy using data from the PARADIGM trial, evaluate the effect of treatment on these changes, and investigate their association with patient outcomes.
Basic objectives2 - Others
Eligibility:
Age-lower limit - Not applicable
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - 1) Patients who participated in the main study of the PARADIGM trial and provided consent for ancillary studies.
2) Patients enrolled in the PARADIGM trial between May 2015 and June 2017.
3) Patients whose study information has been disclosed through an opt-out process and who have not declined participation.
Key exclusion criteria - Patients who were excluded from data analysis in the PARADIGM trial
Target Size - 790
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2025 Year 11 Month 05 Day
Anticipated trial start date - 2025 Year 11 Month 05 Day
Last follow-up date - 2027 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068316
Disclaimer: Curated by HT Syndication.
